Overview

Effect on Weight Loss of Exenatide Versus Placebo

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfonylurea. Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide